HCLTECH
16.1.2023 13:14:41 CET | Business Wire | Press release
HCLTech, a leading global technology company, is joining governments, businesses and civil society from across the world at the World Economic Forum (WEF) 2023 in Davos to facilitate dialogue and collaboration for a sustainable planet and inclusive growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005173/en/
HCLTech pavilion at Promenade66, Davos (Photo: Business Wire)
HCLTech is proud of its long-standing strategic partnership with the WEF. The HCLTech Pavilion at WEF 2023 showcases the company’s new brand identity and purpose of bringing together the best of technology and people to supercharge progress for clients, its people, communities and the planet.
Located at Promenade 66, 7270 Davos Platz, the HCLTech Pavilion is fully powered by green energy, underscoring the company’s commitment to a sustainable planet.
As part of HCLTech’s focus on diversity and gender equality, the company is hosting the UN Women’s Gender Equality Hub at its Pavilion. The Hub will feature daily video check-ins, pop-up panel discussions and fireside chats.
HCLTech’s leadership team will join and host global leaders at WEF in thought-provoking sessions around the Annual Meeting’s theme of “Cooperation in a Fragmented World” and discuss solutions to address the diverse crises facing the world.
Roshni Nadar Malhotra, Chairperson, HCLTech will join former U.S. Vice President Al Gore and other distinguished leaders at “Leading the Charge through Earth’s New Normal” - a session to discuss transformative solutions and global collaboration to build a more inclusive, prosperous and sustainable future. She will also join “The Aquapreneur Revolution” - a session hosted by Emma Benameur, Head of Impact and Engagement and Member of the WEF Executive Committee to announce the winners of The Global Freshwater Innovation Challenge under HCL Group and UpLink’s quest to find innovative solutions for freshwater conservation.
C Vijayakumar, CEO & Managing Director, HCLTech will share his vision at “Preparing One Billion People for Tomorrow’s Economy” - a session to discuss critical interventions needed to skill one billion people by 2030 in a world being rapidly transformed by technology. He will be joined by Saadia Zahidi, Managing Director, WEF and business leaders from Merck, Manpower Group and UBA Group.
In addition, Santhosh Jayaram, Global Head of Sustainability, HCLTech will spearhead the “Sustainability Dialogues with HCLTech” - a series of sessions with industry-leading business and thought leaders to engage in an open dialogue, focused on the most pressing agendas and topics around sustainability.
Srinivasan Seshadri, Corporate Vice President and Global Head of Financial Services, HCLTech will be part of “Operating Models in the Wake of Deglobalization” - a session on the growing need of businesses for innovative models to insulate them from the growing volatility in the global environment.
HCLTech CMO Jill Kouri will speak at “Generation Equality Pop Up, Role of Women in Climate Action” - a session that will include Kate Behncken, Corporate Vice President, Microsoft Philanthropies and Caitlin Kraft Buchman, Founder, CEO, Women@TheTable.
To learn more about HCLTech@WEF 2023 visit https://www.hcltech.com/world-economic-forum.
About HCLTech
HCLTech is a global technology company, home to 222,000+ people across 60 countries, delivering industry-leading capabilities centered around digital, engineering and cloud, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending December, 2022 totaled $12.3 billion. To learn how we can supercharge progress for you, visit hcltech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005173/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom